Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7018-03 Phase 1 Dose Escalation in Relapsed/Refractory Non-Hodgkin Lymphoma
jRCT2021240028Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ONO-7018 in non-Hodgkin lymphoma (NHL), sponsored by Ono Pharmaceutical. Primary endpoint: Safety and tolerability of ONO-7018. Started Nov 2024; status: completed.
02
Drugs
ONO-7018
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT2021240028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240028.